Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Drtech Corp (214680:KRX), powered by AI.
Drtech Corp is currently trading at ₩1,293. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Drtech Corp on Alpha Lenz.
Drtech Corp's P/E ratio is -4.5.
“Drtech Corp trades at a P/E of -4.5 (undervalued) with modest ROE of -32.1%.”
Ask for details →Drtech Corp, a pioneer in technological advancements, primarily specializes in manufacturing and distributing state-of-the-art medical imaging products. As a vital player in the healthcare technology sector, the company's primary function involves developing innovative digital radiography (DR) solutions pivotal for enhancing diagnostic precision and workflow efficiency in medical facilities. Drtech Corp's offerings significantly impact both the public and private healthcare sectors, facilitating the early detection and treatment of medical conditions through cutting-edge imaging technology. Their products are utilized in hospitals, diagnostic centers, and clinics worldwide, reflecting their commitment to improving health outcomes through superior imaging clarity. The company is recognized for its continuous contribution to healthcare innovation, aiding in advancing global medical standards. With a focus on R&D and quality enhancement, Drtech Corp plays a crucial role in the intersection of technology and healthcare, providing essential tools for medical professionals and radiologists. Founded in South Korea, Drtech Corp remains a key component in the global health infrastructure, offering solutions that not only support effective diagnosis but also drive forward the capabilities of modern medicine.
“Drtech Corp trades at a P/E of -4.5 (undervalued) with modest ROE of -32.1%.”
Ask for details →Drtech Corp (ticker: 214680) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 363 employees. Market cap is $107.9B.
The current price is ₩1,293 with a P/E ratio of -4.49x and P/B of 1.41x.
ROE is -32.14% and operating margin is -11.95%. Annual revenue is $116.3B.